First report of an acute case of Chagas disease in the municipality of Miraflores, Guaviare, Colombia
DOI:
https://doi.org/10.17843/rpmesp.2024.412.13271Keywords:
Benznidazole, Case Reports, Chagas disease, Nifurtimox, Trypanosoma cruziAbstract
We present a case of acute phase Chagas disease in a 40-year-old male patient from Vereda Buenos Aires, Municipality of Miraflores, Department of Guaviare. The patient attended the emergency department with fever, headache, asthenia, adynamia and dysuria. The blood smear and urinalysis were positive for symptomatic urinary tract infection, but negative for malaria. Five days later the diagnosis of acute phase Chagas disease was confirmed after a positive result for Trypanosoma cruzi. The patient was treated with nifurtimox and benznidazole, his contacts and risk areas were investigated, an active entomological community and institutional search was carried out, as well as in the reservoirs, finally, laboratory surveillance for possible cases of infection in the community was conducted. Five cases with similar symptoms were identified, but parasitological tests were negative. Health education measures were implemented to prevent the spread of the disease.
Downloads
References
Rassi Jr. A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388-402. doi: 10.1016/S0140-6736(10)60061-X.
de Sousa AS, Vermeij D, Ramos AN Jr, Luquetti AO. Chagas disease. Lancet. 2024;403(10422):203-218. doi: 10.1016/S0140-6736(23)01787-7.
Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions—A comprehensive review. Mem Inst Oswaldo Cruz. 2015;110(3):277–82. doi: 10.1590/0074-0276140362.
Vega S, Cabrera R, Álvarez CA, Uribe-Vilca I, Guerrero-Quincho S, Ancca-Juárez J, et al. Clinical and epidemiological characteristics of
cases of acute Chagas disease in the Peruvian Amazon basin, 2009-2016. Rev Peru Med Exp Salud Publica. 2021;38(1):70–6. doi: 10.17843/rpmesp.2021.381.6286.
Olivera MJ, Muñoz L. Exploring the latency period in Chagas disease: duration and determinants in a cohort from Colombia. Trans R Soc Trop Med Hyg. 2024:trae004. doi: 10.1093/trstmh/trae004.
World Helalth Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33-43.
Olivera MJ, Fory JA, Porras JF, Buitrago G. Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. PLoS One. 2019;14(1).
Instituto Nacional de Salud. Protocolo de vigilancia de Chagas. Bogota, DC; 2018. Available from: https://www.ins.gov.co/buscador-eventos/Lineamientos/Pro_Chagas%202022.pdf.
Padilla-Rodríguez JC, Olivera MJ, Ahumada-Franco ML, Paredes-Medina AE. Malaria risk stratification in Colombia 2010 to 2019. PLoS One. 2021;16(3):e0247811. doi: 10.1371/journal.pone.0247811.
Organización Panamericana de la Salud. Síntesis de evidencia: Guía para el diagnóstico y el tratamiento de la enfermedad de Chagas. Rev Panam Salud Publica. 2020;44:e28. doi: 10.26633/RPSP.2020.28.
Olivera MJ, Fory JA, Olivera AJ. Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines. Rev Soc Bras Med Trop. 2017;50(6):748-55. doi: 10.1590/0037-8682-0399-2016.
Olivera MJ, Fory JA, Olivera AJ. Quality assessment of clinical practice guidelines for Chagas disease. Rev Soc Bras Med Trop. 2015;48(3):343-6. doi: 10.1590/0037-8682-0251-2014.
Olivera MJ, Cucunuba ZM, Alvarez CA, Nicholls RS. Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults. Am J Trop Med Hyg. 2015;93(6):1224–30. doi: 10.4269/ajtmh.15-0256.
Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82-94. doi: 10.1016/S0140-6736(17)31612-4.
Schijman AG, Alonso-Padilla J, Longhi SA, Picado A. Parasitological, serological and molecular diagnosis of acute and chronic Chagas disease: from field to laboratory. Mem Inst Oswaldo Cruz. 2022;117:e200444. doi: 10.1590/0074-02760200444.
Gurgel-Gonçalves R. Stronger control-surveillance systems for vector-borne Chagas disease. Mem Inst Oswaldo Cruz. 2023;117:e210130chgsb. doi: 10.1590/0074-02760210130chgsb.
Olivera MJ, Buitrago G. Economic costs of Chagas disease in Colombia in 2017: A social perspective. Int J Infect Dis. 2020;91:196–201. doi: 10.1016/j.ijid.2019.11.022.
BMC Medicine. Putting Chagas disease on the global health agenda. BMC Med. 2023;21(1):188. doi: 10.1186/s12916-023-02885-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 José Ziadé Benítez , Diana Cedeño Díaz, Luz Alba Colorado, Laureano Mosquera Murillo, María Trinidad Orozco , Sandra Vallecilla , Julio Cesar Padilla , Mario J. Olivera
This work is licensed under a Creative Commons Attribution 4.0 International License.